Annual SGA
$3.23 M
+$285.70 K+9.70%
December 31, 2023
Summary
- As of February 7, 2025, MNPR annual SGA is $3.23 million, with the most recent change of +$285.70 thousand (+9.70%) on December 31, 2023.
- During the last 3 years, MNPR annual SGA has risen by +$787.30 thousand (+32.22%).
- MNPR annual SGA is now at all-time high.
Performance
MNPR SGA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly SGA
$590.60 K
-$67.20 K-10.22%
September 30, 2024
Summary
- As of February 7, 2025, MNPR quarterly SGA is $590.60 thousand, with the most recent change of -$67.20 thousand (-10.22%) on September 30, 2024.
- Over the past year, MNPR quarterly SGA has dropped by -$166.70 thousand (-22.01%).
- MNPR quarterly SGA is now -32.61% below its all-time high of $876.40 thousand, reached on December 31, 2023.
Performance
MNPR Quarterly SGA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM SGA
-$250.48 M
-$6.47 M-2.65%
September 30, 2024
Summary
- As of February 7, 2025, MNPR TTM SGA is -$250.48 million, with the most recent change of -$6.47 million (-2.65%) on September 30, 2024.
- Over the past year, MNPR TTM SGA has dropped by -$253.60 million (-8136.81%).
- MNPR TTM SGA is now -1259.27% below its all-time high of -$18.43 million.
Performance
MNPR TTM SGA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Selling, General & Administrative Expenses Formula
SGA = Total Operating Expenses - Cost of Goods Sold - Research & Development
MNPR Selling, General & Administrative Expenses Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +9.7% | -22.0% | -8136.8% |
| 3 y3 years | +32.2% | -6.5% | -9869.2% |
| 5 y5 years | +107.5% | -14.1% | -10000.0% |
MNPR Selling, General & Administrative Expenses Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +22.7% | -32.6% | at low | -66.9% | at low |
| 5 y | 5-year | at high | +37.2% | -32.6% | +50.6% | -156.8% | at low |
| alltime | all time | at high | +254.1% | -32.6% | +174.4% | -1259.3% | at low |
Monopar Therapeutics Selling, General & Administrative Expenses History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | $590.60 K(-10.2%) | $2.88 M(-5.2%) |
| Jun 2024 | - | $657.80 K(-13.1%) | $3.04 M(-2.4%) |
| Mar 2024 | - | $757.30 K(-13.6%) | $3.12 M(-3.5%) |
| Dec 2023 | $3.23 M(+9.7%) | $876.40 K(+16.9%) | $3.23 M(+2.2%) |
| Sep 2023 | - | $749.50 K(+2.2%) | $3.16 M(+2.4%) |
| Jun 2023 | - | $733.50 K(-15.9%) | $3.09 M(+1.6%) |
| Mar 2023 | - | $871.70 K(+8.2%) | $3.04 M(+3.1%) |
| Dec 2022 | $2.95 M(+11.8%) | $806.00 K(+19.4%) | $2.95 M(+3.8%) |
| Sep 2022 | - | $675.10 K(-1.4%) | $2.84 M(+1.6%) |
| Jun 2022 | - | $684.90 K(-12.1%) | $2.79 M(+2.5%) |
| Mar 2022 | - | $779.30 K(+11.6%) | $2.73 M(+3.5%) |
| Dec 2021 | $2.63 M(+7.8%) | $698.40 K(+10.6%) | $2.63 M(+2.7%) |
| Sep 2021 | - | $631.70 K(+2.5%) | $2.56 M(+10.3%) |
| Jun 2021 | - | $616.00 K(-10.5%) | $2.32 M(-0.7%) |
| Mar 2021 | - | $687.90 K(+9.5%) | $2.34 M(-4.2%) |
| Dec 2020 | $2.44 M | $628.40 K(+60.3%) | $2.44 M(-0.5%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2020 | - | $392.10 K(-37.9%) | $2.46 M(-5.7%) |
| Jun 2020 | - | $631.60 K(-20.2%) | $2.60 M(+1.1%) |
| Mar 2020 | - | $791.60 K(+23.5%) | $2.58 M(+9.3%) |
| Dec 2019 | $2.36 M(+51.3%) | $641.10 K(+18.8%) | $2.36 M(+11.1%) |
| Sep 2019 | - | $539.60 K(-10.5%) | $2.12 M(+9.0%) |
| Jun 2019 | - | $602.80 K(+5.4%) | $1.94 M(+15.1%) |
| Mar 2019 | - | $571.70 K(+41.0%) | $1.69 M(+8.5%) |
| Dec 2018 | $1.56 M(+33.5%) | $405.40 K(+11.4%) | $1.56 M(-1.4%) |
| Sep 2018 | - | $363.80 K(+4.8%) | $1.58 M(+10.4%) |
| Jun 2018 | - | $347.30 K(-21.1%) | $1.43 M(+4.7%) |
| Mar 2018 | - | $440.10 K(+2.9%) | $1.37 M(+17.1%) |
| Dec 2017 | $1.17 M(+27.8%) | $427.50 K(+98.7%) | $1.17 M(+57.9%) |
| Sep 2017 | - | $215.20 K(-24.1%) | $738.70 K(+41.1%) |
| Jun 2017 | - | $283.40 K(+18.0%) | $523.50 K(+118.0%) |
| Mar 2017 | - | $240.10 K | $240.10 K |
| Dec 2016 | $912.50 K | - | - |
FAQ
- What is Monopar Therapeutics annual SGA?
- What is the all time high annual SGA for Monopar Therapeutics?
- What is Monopar Therapeutics annual SGA year-on-year change?
- What is Monopar Therapeutics quarterly SGA?
- What is the all time high quarterly SGA for Monopar Therapeutics?
- What is Monopar Therapeutics quarterly SGA year-on-year change?
- What is Monopar Therapeutics TTM SGA?
- What is the all time high TTM SGA for Monopar Therapeutics?
- What is Monopar Therapeutics TTM SGA year-on-year change?
What is Monopar Therapeutics annual SGA?
The current annual SGA of MNPR is $3.23 M
What is the all time high annual SGA for Monopar Therapeutics?
Monopar Therapeutics all-time high annual SGA is $3.23 M
What is Monopar Therapeutics annual SGA year-on-year change?
Over the past year, MNPR annual SGA has changed by +$285.70 K (+9.70%)
What is Monopar Therapeutics quarterly SGA?
The current quarterly SGA of MNPR is $590.60 K
What is the all time high quarterly SGA for Monopar Therapeutics?
Monopar Therapeutics all-time high quarterly SGA is $876.40 K
What is Monopar Therapeutics quarterly SGA year-on-year change?
Over the past year, MNPR quarterly SGA has changed by -$166.70 K (-22.01%)
What is Monopar Therapeutics TTM SGA?
The current TTM SGA of MNPR is -$250.48 M
What is the all time high TTM SGA for Monopar Therapeutics?
Monopar Therapeutics all-time high TTM SGA is -$18.43 M
What is Monopar Therapeutics TTM SGA year-on-year change?
Over the past year, MNPR TTM SGA has changed by -$253.60 M (-8136.81%)